Piper Jaffray Companies set a $48.00 price objective on Biohaven Pharmaceutical (NYSE:BHVN) in a report published on Monday morning. The brokerage currently has a buy rating on the stock.

Several other equities research analysts have also weighed in on the stock. BidaskClub upgraded shares of Biohaven Pharmaceutical from a buy rating to a strong-buy rating in a research note on Thursday, September 28th. Needham & Company LLC reiterated a buy rating and set a $36.00 price objective on shares of Biohaven Pharmaceutical in a research note on Wednesday, November 15th. William Blair reiterated an outperform rating on shares of Biohaven Pharmaceutical in a research note on Tuesday, October 3rd. Finally, Zacks Investment Research upgraded shares of Biohaven Pharmaceutical from a sell rating to a hold rating in a research note on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. Biohaven Pharmaceutical currently has a consensus rating of Buy and an average price target of $37.17.

Biohaven Pharmaceutical (BHVN) opened at $21.93 on Monday. Biohaven Pharmaceutical has a 12-month low of $17.00 and a 12-month high of $39.51.

In other Biohaven Pharmaceutical news, insider Robert Berman sold 160,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were sold at an average price of $25.76, for a total value of $4,121,600.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Vlad Coric sold 150,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $29.41, for a total transaction of $4,411,500.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 464,131 shares of company stock worth $12,543,701.

Several large investors have recently made changes to their positions in BHVN. VHCP Management II LLC bought a new position in shares of Biohaven Pharmaceutical in the third quarter valued at approximately $60,826,000. Eagle Asset Management Inc. bought a new position in shares of Biohaven Pharmaceutical in the third quarter valued at approximately $32,635,000. Janus Henderson Group PLC bought a new position in shares of Biohaven Pharmaceutical in the third quarter valued at approximately $25,751,000. JPMorgan Chase & Co. bought a new position in shares of Biohaven Pharmaceutical in the third quarter valued at approximately $18,173,000. Finally, Stifel Financial Corp bought a new position in shares of Biohaven Pharmaceutical in the third quarter valued at approximately $15,525,000. Institutional investors own 47.76% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Piper Jaffray Companies Reiterates “$48.00” Price Target for Biohaven Pharmaceutical (BHVN)” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/piper-jaffray-companies-reiterates-48-00-price-target-for-biohaven-pharmaceutical-bhvn/1765349.html.

About Biohaven Pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with Analyst Ratings Network's FREE daily email newsletter.